A CBD brand can spend months developing a great product, only to have a single mislabeled claim trigger an FDA warning letter, a state enforcement action, or worse: a product liability lawsuit with no insurance carrier willing to step in. The CBD market is projected to reach $24.61 billion in 2026, with North America holding an estimated 87% of that share. That kind of growth draws attention from regulators, plaintiff attorneys, and competitors alike. For business owners in this space, getting labeling and compliance claims right isn't a nice-to-have. It's the difference between scaling a legitimate company and watching it collapse under regulatory scrutiny. The rules are shifting fast, and the gap between what brands want to say about their products and what they're legally allowed to say keeps tripping up even experienced operators. This piece breaks down the specific requirements, risks, and strategies that CBD businesses need to understand to protect themselves in 2026.

The Landscape of CBD Labeling Requirements

CBD labeling sits at the intersection of federal food and drug law, state cannabis regulations, and consumer protection statutes. No single rulebook covers everything, which is exactly why so many brands get it wrong. The federal government still hasn't finalized a comprehensive regulatory framework for CBD products, leaving companies to piece together guidance from multiple agencies. That patchwork creates real risk for businesses operating across state lines, because a label that's compliant in Colorado might violate rules in New York or California.

FDA Guidelines and Federal Restrictions

The FDA has been clear about one thing: CBD cannot be marketed as a dietary supplement or added to conventional food under current federal law. That hasn't stopped thousands of companies from doing exactly that, but enforcement actions have picked up. The agency's enforcement memo on CBD and health claims signals a harder line, particularly against brands making disease-related claims. Federal labels must include net weight, ingredient lists, manufacturer information, and proper allergen disclosures. Any product that crosses into drug claim territory, such as claiming to treat anxiety or chronic pain, risks classification as an unapproved drug.

State-Specific Labeling Mandates

State requirements vary wildly. New York, for example, requires specific product labeling under its cannabis regulations, including THC content per serving, total cannabinoid profiles, and clear warnings. California mandates Proposition 65 warnings on many CBD products. Florida requires QR codes linking to certificates of analysis. Some states require child-resistant packaging for all ingestible CBD products, while others only require it for products above certain THC thresholds. If you sell in multiple states, your label essentially needs to satisfy the strictest requirements across all of them.

Mandatory Elements: QR Codes and Batch Numbers

Batch-level traceability has become the standard expectation. Most states with active CBD regulations now require batch or lot numbers on every product, and many require scannable QR codes that link directly to third-party lab results. This isn't just a regulatory checkbox: it's a liability shield. When a customer or regulator can scan a code and see exactly what's in the product, it demonstrates transparency that matters in court. Brands that skip this step are essentially choosing to operate without a safety net.

Navigating Compliance and Health Claims

The language on your label and in your marketing materials carries real legal weight. One poorly worded Instagram post or product description can constitute a health claim that puts your entire operation at risk.

The Risk of Medical and Therapeutic Claims

Saying your CBD tincture "treats insomnia" or "cures inflammation" is a medical claim, and it's illegal without FDA approval. The consequences go beyond warning letters. Medical claims can void your product liability insurance, expose you to FTC enforcement, and open the door to class action lawsuits from consumers who relied on those claims. Recent regulatory tightening means that popular CBD products are being pulled from shelves precisely because their marketing crossed these lines. Even implied claims, like placing a CBD product next to medical imagery or using testimonials that reference specific conditions, can trigger enforcement.

Permissible Structure-Function Language

Structure-function claims are the safe zone, but the boundaries are narrow. You can say a product "supports joint health" or "promotes relaxation" because those describe how a substance affects the body's normal function. You cannot say it "reduces arthritis pain" or "treats anxiety disorder." The distinction feels subtle, but regulators take it seriously. Every structure-function claim must include the disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Missing that disclaimer is one of the most common compliance failures.

Comparison of Industry Labeling Standards

How Recent Hemp Regulations Are Reshaping Compliance

The regulatory environment shifted significantly in late 2025 and into 2026. New federal proposals have tightened the definition of hemp-derived products, and many CBD brands are facing what industry analysts call a compliance cliff as rules tighten around hemp products. Products that were previously sold without issue may now need reformulation, relabeling, or removal from certain markets. MOCRA (the Modernization of Cosmetics Regulation Act) has also brought new compliance requirements for CBD topicals, including facility registration and adverse event reporting. Brands that haven't updated their compliance programs since 2024 are operating on borrowed time.

Mitigating Liability Through Transparent Labeling

Good labeling isn't just about avoiding fines. It's your first line of defense in a product liability claim. When a plaintiff alleges harm from a CBD product, the label is exhibit A. If it's accurate, complete, and includes proper warnings, your legal position is dramatically stronger.

The Role of Third-Party Testing and COAs

Certificates of Analysis from ISO-accredited labs are non-negotiable for any serious CBD operation. A COA should confirm cannabinoid potency, verify THC levels are within legal limits, and screen for contaminants like heavy metals, pesticides, and residual solvents. The COA needs to match the batch number on the product. Sounds obvious, but we've seen businesses use a single COA for months of production runs, which creates a massive liability gap. At GrayStone Insurance Group, our brokers have seen product liability claims hinge on whether a company could produce batch-specific testing documentation. Companies that can't produce matching COAs often find themselves uninsurable after a claim.

Warning Statements and Disclaimers

Beyond the structure-function disclaimer, CBD products should include warnings about pregnancy and nursing, potential drug interactions, age restrictions, and dosage guidance. California's Proposition 65 warnings are mandatory for products sold in the state. Some brands resist adding warnings because they think it hurts sales, but the opposite is true from a risk perspective. Clear warnings demonstrate that a manufacturer took reasonable steps to inform consumers, which is exactly what a defense attorney needs in a product liability case.

Common Questions About CBD Compliance

Does the FDA regulate CBD products? The FDA has authority over CBD products marketed with health claims or sold as food or dietary supplements. While comprehensive regulations haven't been finalized, the agency actively issues warning letters and can pursue enforcement actions.

Can I sell CBD products across state lines? Yes, but your labeling must comply with every state where you sell. Requirements vary significantly, so multi-state sellers should build labels around the strictest applicable standards.

What happens if I make a health claim on my CBD label? You risk FDA warning letters, FTC enforcement, state-level penalties, and class action lawsuits. Your product liability insurance may also deny coverage for claims arising from illegal marketing.

Do I need third-party lab testing for every batch? Most state regulations require batch-specific testing, and it's considered standard practice industry-wide. Skipping batch testing creates both regulatory and liability exposure.

How often should I review my labels for compliance? At minimum, quarterly. Regulations are changing rapidly in 2026, and a label that was compliant six months ago may not meet current requirements.

Why CBD Businesses Struggle to Get Insured

Insurance carriers view CBD as a high-risk category for good reason. The regulatory ambiguity, the prevalence of unsubstantiated claims, and the potential for contamination all create underwriting challenges. Many standard commercial carriers simply decline CBD accounts outright. Specialty agencies like GrayStone Insurance Group focus specifically on hard-to-place risks, including CBD and hemp operations. With brokers averaging 20 years of experience and a data-driven approach to risk modeling, finding coverage becomes a solvable problem rather than an impossible one.

The Connection Between Labeling and Insurability

Here's something most CBD operators don't realize: your labeling practices directly affect your ability to get and keep insurance. Underwriters review product labels during the application process. If they see medical claims, missing disclaimers, or no evidence of third-party testing, they'll either decline coverage or price the policy punitively. Clean labels with proper compliance documentation signal a well-run operation, and that translates to better coverage terms and lower premiums.

Environmental and Chemical Reporting Requirements

A newer wrinkle for CBD businesses involves TSCA PFAS reporting requirements that affect cannabis and hemp operations. If your products or packaging contain PFAS chemicals, you may have federal reporting obligations in 2026. This is an area most CBD brands haven't even considered, but non-compliance carries significant penalties. Environmental liability is a coverage gap that can blindside businesses that think product liability is their only concern.

Building a Compliance-First Culture

The most successful CBD brands treat compliance as a competitive advantage, not a burden. They hire regulatory counsel, invest in quality management systems, and train every team member who touches product development or marketing on what they can and can't say. This approach pays dividends beyond avoiding fines: it builds consumer trust, improves retail placement opportunities, and makes the company far more attractive to insurers and investors.

Protecting Your Business Long-Term

CBD compliance isn't a one-time project. It's an ongoing discipline that touches every part of your business, from formulation to marketing to customer service. The brands that thrive in this market will be the ones that treat labeling accuracy and regulatory compliance as core business functions, not afterthoughts. Start with a label audit against current federal and state requirements. Get batch-specific COAs from accredited labs. Strip any language that even hints at medical claims. Then make sure your insurance program actually covers the products you're selling, because a policy full of exclusions is barely better than no policy at all. If you're running a CBD operation and struggling to find coverage that matches your actual risk profile, reach out to GrayStone Insurance Group. With a 94% client retention rate and deep experience insuring complex, high-risk businesses, they can help you build a coverage strategy that holds up when it matters most.